JHS Secures Multi-Million Dollar Contracts to Manufacture Sterile Parenteral Products
News Feb 23, 2012
Jubilant HollisterStier has announced that its Contract Manufacturing & Services division has recently secured contracts with four innovator life science companies for the commercial manufacturing of sterile parenteral products for sale in the United States and Europe.
These agreements will be executed at its Spokane, Washington facility for contract manufacturing of products ranging from liquid to lyophilization presentations, across a variety of patient indications.
The total value of these contracts is over US $ 90 million to be delivered over a 5 year period. Commercial transfer to the Jubilant HollisterStier manufacturing facility has commenced for all contracts.
“We have successfully helped provide safe and effective products to innovator Pharmaceutical and Biotechnology companies over the years and are committed to do so for these products as well. We are pleased to offer our support in the development and manufacture of highly complex products through the application of leading scientific solutions and utmost dedication to quality and customer service. This expansion of our globally leading parenteral manufacturing capabilities is a further outcome of our strategy to extend our offering across products and geographies.” said Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier.
Commenting on the multi-million dollar award, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said, “We are pleased with signing of these long term contracts with innovator pharma companies to serve the regulated markets of US and Europe and is a direct result of our increased business development efforts leading to higher utilization of our existing capacity. Jubilant is one of the leading manufacturers of sterile both liquid and lyophilized products in North America.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE